An original patient-derived xenograft of prostate cancer with cyst formation.
The high rate of failure of new agents in oncology clinical trials indicates a weak understanding of the complexity of human cancer. Recent understanding of the mechanisms underlying castration resistance in prostate cancer led to the development of new agents targeting the androgen receptor pathway; however, their effectiveness is limited. Hence, there is a need for experimental systems that are able to better reproduce the biological diversity of prostate cancer in preclinical settings. In this study, we established a unique patient-derived xenograft (PDX) model to identify biomarkers for treatment efficacy and resistance and better understand prostate cancer biology.



A prostate cancer tissue sample from a Japanese patient was transplanted subcutaneously into male, severe combined immune-deficient (SCID) mice and this PDX mouse model was named KUCaP3. Sequential tumor volume changes were observed before and after castration. Androgen receptor (AR), prostate-specific antigen (PSA), and other molecular markers were examined immunohistochemically. Sequence analysis of AR was also performed to detect mutations. Proteomic analysis of cyst fluid and sera samples of KUCaP3 mice were analyzed by mass spectrometry (MS).



KUCaP3 cell line, derived from human tissue, was successfully and serially passaged in vivo with approximately 60% take rate. KUCaP3 exhibited cyst formation, showed androgen-dependent growth initially, and developed castration-resistant growth several months after castration of the mice. Immunohistochemical analysis showed that KUCaP3 was positive for AR, PSA, CK18, and α-methyl acyl-coenzyme A racemase, but negative for CK5/6 and ERG. The AR gene in KUCaP3 cells contained a substitution from CAT (histidine) to TAT (tyrosine) at the nucleotide positions corresponding to codon 875 (H875Y) in the ligand-binding domain. Chemiluminescent immunoassay revealed higher levels of PSA in cystic fluid and the serum of KUCaP3-bearing mice. MS analysis detected 23 proteins of human origin in cystic fluids of KUCaP3.



We developed KUCaP3, an androgen-dependent PDX model with cyst formation. Several proteins including PSA were detected in the cystic fluid and sera of tumor-bearing mice. This original PDX model has the potential to be used as a clinically relevant model to evaluate molecular markers for prostate cancer diagnosis and treatment. Prostate 76:994-1003, 2016. © 2016 Wiley Periodicals, Inc.
Department of Urology, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Takeshi
T
Yoshikawa
Department of Urology, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Go
G
Kobori
Department of Urology, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Takayuki
T
Goto
Department of Urology, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Shusuke
S
Akamatsu
Department of Urology, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Naoki
N
Terada
Department of Urology, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Takashi
T
Kobayashi
Toray Industries, Inc., New Frontiers Research Laboratories, Kamakura, Kanagawa, Japan.
Yoshinori
Y
Tanaka
Toray Industries, Inc., New Frontiers Research Laboratories, Kamakura, Kanagawa, Japan.
Giman
G
Jung
Department of Urology, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Tomomi
T
Kamba
Department of Urology, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Osamu
O
Ogawa
Department of Urology, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Takahiro
T
Inoue
D000368:Aged; D000818:Animals; D014408:Biomarkers, Tumor / Q000032:analysis; D045744:Cell Line, Tumor; D020420:Cyst Fluid; D003560:Cysts / Q000473:pathology; D064593:Heterografts; D006801:Humans; D007150:Immunohistochemistry; D007564:Japan; D008297:Male; D051379:Mice; D016513:Mice, SCID; D009154:Mutation; D009368:Neoplasm Transplantation / Q000473:pathology*; D009919:Orchiectomy; D017430:Prostate-Specific Antigen / Q000032:analysis / Q000097:blood; D011471:Prostatic Neoplasms / Q000737:chemistry / Q000473:pathology*; D064129:Prostatic Neoplasms, Castration-Resistant; D011944:Receptors, Androgen / Q000032:analysis / Q000235:genetics
D014408:Biomarkers, Tumor; D011944:Receptors, Androgen; D017430:Prostate-Specific Antigen
PDX; androgen-dependent; castration-resistant; mass-spectrometry; prostate cancer